Komori
Share Issuance and Disposal4528ONO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Completion of Payment for the Disposition of Treasury Shares as Service-Based and Performance-Linked Restricted Stock Compensation

Payment procedures for the disposition of treasury shares as service-based and performance-linked restricted stock compensation, as resolved on 18 June 2026, have been completed. A total of 199,900 shares were disposed of to directors and executive officers.

Worth reading
35Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
199900
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Disposition of treasury shares as service-based and performance-linked restricted stock compensation

Who receives how much

Service-based 20,900 shares / Performance-linked 179,000 shares

Directors of the Company (excluding outside directors)3 / Service-based: 20,900 shares; performance-linked: 94,500 shares
The Company's executive officers who do not concurrently serve as directors13 / 84,500 shares

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

¥2,249.5 per share
Total issue value

Service-based ¥47,014,550 / Performance-linked ¥402,660,500

Categories and Number of Persons Covered
Category Directors of the Company (excluding outside directors) / Number of Employees 3 / Number of allocated shares Service-based: 20,900 shares; performance-linked: 94,500 shares, Category The Company's executive officers who do not concurrently serve as directors / Number of Employees 13 / Number of allocated shares 84,500 shares
Payment date
10 July 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalDisposition of treasury shares as service-based and performance-linked restricted stock compensation
Number of shares to be issued or disposed ofService-based 20,900 shares / Performance-linked 179,000 shares
Issue price and disposal price¥2,249.5 per share
Total issue valueService-based ¥47,014,550 / Performance-linked ¥402,660,500
Payment date10 July 2026
Intended allotteeName Directors of the Company (excluding outside directors) / Number of Employees 3 / Number of Shares Service-based: 20,900 shares; performance-linked: 94,500 shares, Name The Company's executive officers who do not concurrently serve as directors / Number of Employees 13 / Number of Shares 84,500 shares
Categories and Number of Persons CoveredCategory Directors of the Company (excluding outside directors) / Number of Employees 3 / Number of allocated shares Service-based: 20,900 shares; performance-linked: 94,500 shares, Category The Company's executive officers who do not concurrently serve as directors / Number of Employees 13 / Number of allocated shares 84,500 shares
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The shares were disposed of as service-based and performance-linked restricted stock compensation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the Disposition of Treasury Shares as Service-Based and Performance-Linked Restricted Stock Compensation | ONO PHARMACEUTICAL CO.,LTD. (4528) timely disclosure | Komori